Cargando…

Treatment policy change to dihydroartemisinin–piperaquine contributes to the reduction of adverse maternal and pregnancy outcomes

BACKGROUND: In Papua, Indonesia, maternal malaria is prevalent, multidrug resistant and associated with adverse outcomes for mother and baby. In March 2006, anti-malarial policy was revised for the second and third trimester of pregnancy to dihydroartemisinin–piperaquine (DHP) for all species of mal...

Descripción completa

Detalles Bibliográficos
Autores principales: Poespoprodjo, Jeanne Rini, Fobia, Wendelina, Kenangalem, Enny, Lampah, Daniel A, Sugiarto, Paulus, Tjitra, Emiliana, Anstey, Nicholas M, Price, Richard N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4501192/
https://www.ncbi.nlm.nih.gov/pubmed/26169783
http://dx.doi.org/10.1186/s12936-015-0794-0
_version_ 1782381030052724736
author Poespoprodjo, Jeanne Rini
Fobia, Wendelina
Kenangalem, Enny
Lampah, Daniel A
Sugiarto, Paulus
Tjitra, Emiliana
Anstey, Nicholas M
Price, Richard N
author_facet Poespoprodjo, Jeanne Rini
Fobia, Wendelina
Kenangalem, Enny
Lampah, Daniel A
Sugiarto, Paulus
Tjitra, Emiliana
Anstey, Nicholas M
Price, Richard N
author_sort Poespoprodjo, Jeanne Rini
collection PubMed
description BACKGROUND: In Papua, Indonesia, maternal malaria is prevalent, multidrug resistant and associated with adverse outcomes for mother and baby. In March 2006, anti-malarial policy was revised for the second and third trimester of pregnancy to dihydroartemisinin–piperaquine (DHP) for all species of malaria. This study presents the temporal analysis of adverse outcomes in pregnancy and early life following this policy change. METHODS: From April 2004 to May 2010, a standardized questionnaire was used to collect information from all pregnant women admitted to the maternity ward. A physical examination was performed on all live birth newborns. The relative risks (RR) and the associated population attributable risks (PAR) of adverse outcomes in women with a history of malaria treatment to the risk in those without a history of malaria during the current pregnancy were examined to evaluate the temporal trends before and after DHP deployment. RESULTS: Of 6,556 women enrolled with known pregnancy outcome, 1,018 (16%) reported prior anti-malarial treatment during their pregnancy. The proportion of women with malaria reporting treatment with DHP rose from 0% in 2004 to 64% (121/189) in 2010. In those with history of malaria during pregnancy, the increasing use of DHP was associated with a 54% fall in the proportion of maternal malaria at delivery and a 98% decrease in congenital malaria (from 7.1% prior to 0.1% after policy change). Overall policy change to more effective treatment was associated with an absolute 2% reduction of maternal severe anaemia and absolute 4.5% decrease in low birth weight babies. CONCLUSIONS: Introduction of highly effective treatment in pregnancy was associated with a reduction of maternal malaria at delivery and improved neonatal outcomes. Ensuring universal access to arteminisin combination therapy (ACT) in pregnancy in an area of multidrug resistance has potential to impact significantly on maternal and infant health. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12936-015-0794-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4501192
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45011922015-07-15 Treatment policy change to dihydroartemisinin–piperaquine contributes to the reduction of adverse maternal and pregnancy outcomes Poespoprodjo, Jeanne Rini Fobia, Wendelina Kenangalem, Enny Lampah, Daniel A Sugiarto, Paulus Tjitra, Emiliana Anstey, Nicholas M Price, Richard N Malar J Research BACKGROUND: In Papua, Indonesia, maternal malaria is prevalent, multidrug resistant and associated with adverse outcomes for mother and baby. In March 2006, anti-malarial policy was revised for the second and third trimester of pregnancy to dihydroartemisinin–piperaquine (DHP) for all species of malaria. This study presents the temporal analysis of adverse outcomes in pregnancy and early life following this policy change. METHODS: From April 2004 to May 2010, a standardized questionnaire was used to collect information from all pregnant women admitted to the maternity ward. A physical examination was performed on all live birth newborns. The relative risks (RR) and the associated population attributable risks (PAR) of adverse outcomes in women with a history of malaria treatment to the risk in those without a history of malaria during the current pregnancy were examined to evaluate the temporal trends before and after DHP deployment. RESULTS: Of 6,556 women enrolled with known pregnancy outcome, 1,018 (16%) reported prior anti-malarial treatment during their pregnancy. The proportion of women with malaria reporting treatment with DHP rose from 0% in 2004 to 64% (121/189) in 2010. In those with history of malaria during pregnancy, the increasing use of DHP was associated with a 54% fall in the proportion of maternal malaria at delivery and a 98% decrease in congenital malaria (from 7.1% prior to 0.1% after policy change). Overall policy change to more effective treatment was associated with an absolute 2% reduction of maternal severe anaemia and absolute 4.5% decrease in low birth weight babies. CONCLUSIONS: Introduction of highly effective treatment in pregnancy was associated with a reduction of maternal malaria at delivery and improved neonatal outcomes. Ensuring universal access to arteminisin combination therapy (ACT) in pregnancy in an area of multidrug resistance has potential to impact significantly on maternal and infant health. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12936-015-0794-0) contains supplementary material, which is available to authorized users. BioMed Central 2015-07-15 /pmc/articles/PMC4501192/ /pubmed/26169783 http://dx.doi.org/10.1186/s12936-015-0794-0 Text en © Poespoprodjo et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Poespoprodjo, Jeanne Rini
Fobia, Wendelina
Kenangalem, Enny
Lampah, Daniel A
Sugiarto, Paulus
Tjitra, Emiliana
Anstey, Nicholas M
Price, Richard N
Treatment policy change to dihydroartemisinin–piperaquine contributes to the reduction of adverse maternal and pregnancy outcomes
title Treatment policy change to dihydroartemisinin–piperaquine contributes to the reduction of adverse maternal and pregnancy outcomes
title_full Treatment policy change to dihydroartemisinin–piperaquine contributes to the reduction of adverse maternal and pregnancy outcomes
title_fullStr Treatment policy change to dihydroartemisinin–piperaquine contributes to the reduction of adverse maternal and pregnancy outcomes
title_full_unstemmed Treatment policy change to dihydroartemisinin–piperaquine contributes to the reduction of adverse maternal and pregnancy outcomes
title_short Treatment policy change to dihydroartemisinin–piperaquine contributes to the reduction of adverse maternal and pregnancy outcomes
title_sort treatment policy change to dihydroartemisinin–piperaquine contributes to the reduction of adverse maternal and pregnancy outcomes
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4501192/
https://www.ncbi.nlm.nih.gov/pubmed/26169783
http://dx.doi.org/10.1186/s12936-015-0794-0
work_keys_str_mv AT poespoprodjojeannerini treatmentpolicychangetodihydroartemisininpiperaquinecontributestothereductionofadversematernalandpregnancyoutcomes
AT fobiawendelina treatmentpolicychangetodihydroartemisininpiperaquinecontributestothereductionofadversematernalandpregnancyoutcomes
AT kenangalemenny treatmentpolicychangetodihydroartemisininpiperaquinecontributestothereductionofadversematernalandpregnancyoutcomes
AT lampahdaniela treatmentpolicychangetodihydroartemisininpiperaquinecontributestothereductionofadversematernalandpregnancyoutcomes
AT sugiartopaulus treatmentpolicychangetodihydroartemisininpiperaquinecontributestothereductionofadversematernalandpregnancyoutcomes
AT tjitraemiliana treatmentpolicychangetodihydroartemisininpiperaquinecontributestothereductionofadversematernalandpregnancyoutcomes
AT ansteynicholasm treatmentpolicychangetodihydroartemisininpiperaquinecontributestothereductionofadversematernalandpregnancyoutcomes
AT pricerichardn treatmentpolicychangetodihydroartemisininpiperaquinecontributestothereductionofadversematernalandpregnancyoutcomes